Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Go back to Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study| (NASDAQ: STRO) | Delayed: 10.79 -0.75 (6.5%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.54 | 52 Week High | $ | |||
| Open | $11.62 | 52 Week Low | $ | |||
| Day High | $11.80 | P/E | N/A | |||
| Day Low | $10.75 | EPS | $ | |||
| Volume | 439,854 | |||||



